1's Reduce Binge Eating Symptoms

Key Points:

• A systematic review and meta-analysis led by UCL found that GLP-1 receptor agonists (e.g., semaglutide, tirzepatide, liraglutide) significantly reduce core symptoms of binge eating disorder (BED), including binge episodes, loss-of-control eating, and emotional eating, beyond their known effects on weight loss.
• These drugs act on the central nervous system to modify reward processing and impulse control, helping to suppress compulsive eating urges, though increased cognitive dietary restraint observed may require further study to determine if it is beneficial or potentially harmful.
• The research highlights the importance of integrating GLP-1 therapies into comprehensive BED treatment plans that include psychological support and social interventions, as medication alone is unlikely to achieve sustainable recovery.
• Most existing trials have high risk of bias, are pharmaceutical-funded, and rarely include participants with formal BED diagnoses, underscoring the need for large, independent, long-term studies focusing on clinically diagnosed populations.
• Despite promising evidence, access to these medications for BED patients through public healthcare remains limited, often forcing patients to seek costly private treatment, a barrier researchers hope to address with further data and advocacy.